# Saw Palmetto Hair Loss Randomized Trial: What the Evidence Says Canonical: https://www.migaku.app/guides/saw-palmetto-hair-loss-randomized-trial-evidence-review Category: evidence-review Summary: Saw Palmetto Hair Loss Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are Last reviewed: 2026-08-12 Reviewed by: Migaku Evidence Review # Saw Palmetto Hair Loss Randomized Trial: What the Evidence Says ## Quick Answer Saw Palmetto Hair Loss Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice. ## Key Takeaways - This page is generated only from sources stored in the Migaku evidence knowledge base. - Current evidence mix: 2 research article. - Claims should be interpreted with the source type, study design, population, and publication date in mind. - This article is educational and does not replace care from a qualified clinician. ## Evidence Map | Source | Evidence type | Level | Date | Identifier | | --- | --- | ---: | --- | --- | | The Safety and Efficacy of a Novel Saw Palmetto ( Serenoa repens ) Extract for Promoting Hair Growth in Adults With Self‐Perceived Thinning Hair: 180‐Day Results | research article | 4 | 2026-02-06 | 10.1111/jocd.70717 | | The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto ( Serenoa repens ) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self‐Perceived Thinning Hair: 90‐Day Results | research article | 4 | 2025-11-30 | 10.1111/jocd.70585 | ## What The Sources Report - The largest mean growth effects were localized in posterior terminal hair count, which increased significantly by 13.0 (22.4) at Day 180 for the active group ( < 0.001), while the mean posterior terminal hair counts for the placebo group decreased by −7.6 (18.4). [Ablon Glynis (2026); evidence level 4] - Serenoa repens Following an analysis of available research data and clinical evidence, a novel, proprietary bioactive fatty acids extract from saw palmetto has been developed for maintaining hair health and treating hair loss (SEREVELLE, formerly USPlus DERM, Valensa International; Eustis, FL). [Ablon Glynis (2025); evidence level 4] - Assessment at 12 weeks revealed significant improvements in hair loss and increased hair density in both male and female subjects which began as early as 4 weeks with an overall high degree of subject satisfaction. [Ablon Glynis (2025); evidence level 4] ## How To Read This Evidence Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade. ## Practical Interpretation For saw palmetto hair loss randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources. ## Limits Of This First Pass This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review. ## References - Ablon Glynis (2026). The Safety and Efficacy of a Novel Saw Palmetto ( Serenoa repens ) Extract for Promoting Hair Growth in Adults With Self‐Perceived Thinning Hair: 180‐Day Results. DOI: 10.1111/jocd.70717. PMCID: PMC12881706. PMID: 41652806. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12881706/ - Ablon Glynis (2025). The Safety and Efficacy of a Proprietary Bioactive Fatty Acids Extract From Saw Palmetto ( Serenoa repens ) for Promoting Hair Growth and Reducing Hair Loss in Adults With Self‐Perceived Thinning Hair: 90‐Day Results. DOI: 10.1111/jocd.70585. PMCID: PMC12665258. PMID: 41319217. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12665258/ ## Safety Note Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.